Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25721187 | 1.00 | FDPS (0.48) | FDPSDNM1CA12CA1CA2 | |
| SCHEMBL471813 | 1.00 | FDPS (0.48) | FDPSDNM1CA12CA1CA2 | |
| Octadecylamine SCHEMBL11051694 | 0.91 | DNM1 (0.59) | FDPSDNM1TSHRMEN1KMT2A | |
| SCHEMBL15219176 | 0.88 | — | — | |
| SCHEMBL17713596 | 0.87 | ACLY (0.47) | FDPSDNM1CA12CA1CA2 | |
| SCHEMBL811798 | 0.83 | FDPS (0.48) | FDPSDNM1CA12CA1CA2 | |
| SCHEMBL4884502 | 0.83 | FDPS (0.48) | FDPSDNM1CA12CA1CA2 | |
| SCHEMBL5805828 | 0.80 | — | — | |
| SCHEMBL1132024 | 0.79 | FDPS (0.45) | FDPSDNM1CA12CA1CA2 | |
| SCHEMBL233689 | 0.79 | FDPS (0.45) | FDPSDNM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108795404-B | Self-suspending proppant for clean water fracturing and preparation method thereof | 关中原 | 2021-09-28 | — | — | CN | claimed |
| CN-119661808-A | Water-based wood-like polyurethane and preparation method thereof | 浙江德美博士达高分子材料有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-108795404-B | Self-suspending proppant for clean water fracturing and preparation method thereof | 关中原 | 2021-09-28 | — | — | CN | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| EP-1256276-B1 | METHOD OF TREATING SEEDS | SAKATA SEED CORP (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2006091297-A2 | MOLECULES TO ENHANCE PERCUTANEOUS DELIVERY AND METHODS FOR DISCOVERY THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20030115794-A1 | Method for treating seeds | SAKATA SEED CORPORATION (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1256276-A1 | METHOD OF TREATING SEEDS | Sakata Seed Corporation (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | NOTUM, TRPV1, TRPV4 | FDPS 513/4885DNM1 2823/4885CA12 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.